SCHEMBL20135405

SCHEMBL20135405

COC(=O)c1ccc(C(=O)C(C)(C)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.57
CA2 P00918 4/20 0.57
CA12 O43570 2/20 0.57
CA7 P43166 2/20 0.57
CA9 Q16790 2/20 0.57
CA14 Q9ULX7 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
TSHR P16473 1/20 0.54
MAPT P10636 5/20 0.52
ALDH1A1 P00352 2/20 0.52
NOTUM Q6P988 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10944738 0.94 CA1 (0.52) CA1CA2CA12CA7CA9
SCHEMBL6919651 0.85 CA1 (0.59) CA1CA2CA12CA7CA9
SCHEMBL11298330 0.84 CA2 (0.46) CA2TSHRALDH1A1SMN1; SMN2
SCHEMBL23600 0.82 CA1 (0.80) CA1CA2CA12CA7CA9
SCHEMBL28993944 0.82 CA1 (0.80) CA1CA2CA12CA7CA9
SCHEMBL20135443 0.82 CA1 (0.55) CA1CA2CA12CA7CA9
Water SCHEMBL22720573 0.79 CA1 (0.76) CA1CA2CA12CA7CA9
SCHEMBL28993277 0.79 CA1 (0.76) CA1CA2CA12CA7CA9
SCHEMBL28531063 0.79 CA1 (0.76) CA1CA2CA12CA7CA9
SCHEMBL28704033 0.79 CA1 (0.76) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220130570-A1 POWER CORD ASSEMBLY CONTAINING RECYCLED AND RENEWABLE POLYMERIC COMPOSITIONS DELL PRODUCTS L.P. (US) 2022-04-28 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CA1 1423/4885CA2 579/4885CA12 1365/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CA1 1245/4885CA2 470/4885CA12 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.